Introduction
============

Acute kidney injury (AKI) is a common complication of critical illnesses, including acute coronary syndrome (ACS). The reported incidence of AKI is approximately 12.0%-36.6% [@B1]-[@B5]. In patients with ACS, AKI is associated with significantly increased mortality and morbidity [@B1]-[@B3], [@B6]. Notably, the severity and duration of AKI are correlated with the risk of chronic kidney disease (CKD) [@B7], [@B8].

Many factors contribute to the development of AKI following ACS [@B9], [@B10], including altered haemodynamics secondary to impaired cardiac output, contrast media exposure, neurohormonal activation, inflammation, oxidative stress, bleeding, acidosis, and hyperglycaemia. In addition, percutaneous coronary intervention (PCI) and intra-aortic balloon pump (IABP) use predispose patients to atheroembolism. Many medications, such as diuretics, angiotensin-converting-enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs), nonsteroidal anti-inflammatory drugs, antibiotics, and vasopressors, may aggravate kidney injury.

Despite advances in research over the past decades, effective treatments for AKI are not available. Prevention and early intervention remain the most effective strategies for AKI of any entity. To date, many individual risk factors for AKI after ACS have been reported [@B2], [@B4], [@B11]. However, the cumulative risk, obtained by combining multiple risk factors, has not been assessed. A practical clinical tool to predict the risk of post-ACS AKI is not available. This study developed a risk-prediction model for incident AKI after PCI for ACS, for enabling clinicians to identify high-risk patients, thereby facilitating effective prevention, prompt intervention for severity reduction, and improvement of clinical outcomes.

Results
=======

Patient characteristics
-----------------------

Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"} summarize the basic characteristics and clinical information of the training and validation cohorts. The training cohort comprised 57,530 patients, among which 44,785 (77.8%) were male, the mean age was 63.9 years, and 2,670 (4.6%) patients had incident AKI. The validation cohort comprised 24,656 patients, among which 19,077 (77.4%) were male, the mean age was 64.0 years, and 1,159 (4.7%) patients had incident AKI.

Overall, 19 331 patients (23.5%) experienced cardiogenic shock and 9,417 patients (11.5%) received IABP installation. The in-hospital mortality rate was 6.5% (33.8% in patients with AKI, 5.1% in patients without AKI). The rate of de novo dialysis requirement in the AKI patients was 60.5% and 56.6% in the training and validation cohorts, respectively.

In both cohorts, the patients with AKI were more likely to be female, be older, and have a higher prevalence of comorbidities, such as diabetes mellitus, hypertension, coronary artery disease, prior myocardial infarction, heart failure, CKD, prior AKI, prior stroke, peripheral arterial disease, gout, and malignancy.

The patients with AKI had a higher number of intervened vessels and were more likely to experience cardiogenic shock, receive IABP installation, receive ventilator support, receive a higher inotropic dosage, and receive blood transfusion secondary to major bleeding. The patients with AKI had a longer hospital stay and intensive care unit (ICU) stay than did the patients without AKI.

Risk model development: full model and reduced model (ADVANCIS)
---------------------------------------------------------------

As listed in Table [3](#T3){ref-type="table"}, the full model contained 16 variables, including age, diabetes mellitus, ventilator use, prior AKI, number of intervened vessels, CKD, IABP use, cardiogenic shock, female sex, prior stroke, peripheral arterial disease, hypertension, coronary artery disease, heart failure, malignancy, and gout. To develop a simple and convenient tool, 8 variables were selected to generate a reduced model, ADVANCIS, on the basis of the regression coefficients[@B12] (A for [a]{.ul}ge, D for [d]{.ul}iabetes mellitus, V for [v]{.ul}entilator use, A for prior [A]{.ul}KI, N for [n]{.ul}umber of intervened vessels, C for [C]{.ul}KD, I for [I]{.ul}ABP use, and S for cardiogenic [s]{.ul}hock). VIFs of variables included in the ADVANCIS were less than 2 (ranged from 1.01 to 1.53) which indicated there was no apparent problem of multi-collinearity.

The AUROC~full\ model~ and AUROC~reduced\ model~ for incident AKI were 0.879 (95% confidence interval \[CI\]: 0.873-0.886) and 0.874 (95% CI: 0.868-0.881), respectively. This result indicated that the reduced model has a discriminatory ability equal to that of the full model (Figure [2](#F2){ref-type="fig"}).

ADVANCIS score for predicting AKI after PCI for ACS
---------------------------------------------------

The score of each predictor and the risk of incident AKI according to total points are listed in Table [4](#T4){ref-type="table"}. A value of 0 was assigned when a factor was absent, and a value of \>0 was assigned when a factor was present. The scheme of the 8 parameters is described as follows: age score ranged from 0 to 3, diabetes mellitus was scored 0 or 2, ventilator use was scored 0 or 2, prior AKI was scored 0 or 3, number of intervened vessels score ranged from 0 to 2, CKD was scored 0 or 6, IABP use was scored 0 or 1, and cardiogenic shock was scored 0 or 3. The score of each factor was summed to generate the ADVANCIS score, ranging from 0 to 22 points.

A higher ADVANCIS score was associated with a corresponding increase in the risk of AKI (0.5% to 98.2%). A score ≤5 was associated with a probability \<5%, a score ≥13 corresponded to a probability \>50%, and a score ≥18 predicted a probability \>90%.

Validation of ADVANCIS model
----------------------------

The performance of ADVANCIS applied to the validation dataset was satisfactory with an AUROC~reduced\ model~ of 0.8624 (95% CI: 0.8515-0.8733). Moreover, when we restricted the parameter estimates in the validation cohort to be equal to those in the training cohort, the restricted AUROC~reduced\ model~ was 0.8621 (95% CI: 0.8513-0.8730), which was comparable with the unrestricted AUROC~reduced\ model~ (*P* of delta of AUROC = 0.4730). This result indicates the generalizability of the ADVANCIS scores (Figure [3](#F3){ref-type="fig"}).

ADVANCIS score for predicting in-hospital mortality
---------------------------------------------------

The ability of the ADVANCIS score to predict the risk of in-hospital mortality was further evaluated. The AUROC of the ADVANCIS score in discriminating in-hospital mortality in the validation dataset was 0.935 (95% CI: 0.932-0.937) and the optimal cut-off point was 6, with a sensitivity of 92.4% and a specificity of 86.3% (data not shown). We divided the patients into the subgroups low risk, moderate risk, and high risk on the basis of the ADVANCIS score. As illustrated in Figure [4](#F4){ref-type="fig"}, compared with the low (score 0-5) risk group, the odds ratio of in-hospital mortality in the moderate (score 6-7) and high (score 8-22) risk groups was 45.1 and 121.7, respectively, in the training cohort, and 41.9 and 122.3, respectively, in the validation cohort.

Discussion
==========

Previous studies have addressed the incidence and prognostic implications of AKI after ACS [@B1]-[@B3], [@B6]-[@B8]. In our study, the incidence of AKI after receiving PCI for ACS was 4.7%. Consistent with previous studies, the patients with AKI had significantly higher in-hospital morality (33.8% vs 5.1%), a longer ICU stay, and a longer hospital stay.

Many studies have reported the risk factors for AKI following ACS [@B2], [@B4], [@B11]. However, the cumulative risk has rarely been discussed, and a widely accepted practical clinical tool to predict the risk of AKI following ACS is lacking. Some studies [@B13]-[@B19] have proposed risk-scoring models to assess the risk of contrast induced nephropathy (CIN) after PCI or coronary angiography. In 2004, Merhan et al proposed a post-PCI CIN risk score based on a cohort of 35.7% patients with ACS. The score consisted of 8 parameters, namely hypotension, IABP, congestive heart failure, age \> 75 years, anaemia, diabetes, contrast media volume, and baseline serum creatinine \> 1.5 mg/dL or estimated glomerular filtration rate \< 60 mL/min/1.73 m^2^, with satisfactory discriminative power (*c* statistic 0.67) in the validation group [@B13]. This risk model was recommended by the Kidney Disease: Improving Global Outcome AKI work group [@B20]. However, CIN after PCI or coronary angiography shares many, but not all, characteristics with post-ACS AKI. ACS itself causes deleterious haemodynamic, immunologic, and neuroendocrine effects on kidney function apart from the effects of contrast medium. Marenzi et al also proposed a model for CIN prediction in patients with acute myocardial infarction receiving primary PCI. The model consisted of 5 parameters, namely age \> 75 years, anterior wall myocardial infarction, time to reperfusion \> 6 hours, contrast agent volume \> 300 mL, and IABP use [@B15]. Marenzi\'s group further proposed a risk model to predict AKI after ACS by using 4 variables, namely age, left ventricular ejection fraction, serum concentration, and ST-segmental myocardial infarction [@B21].

To our knowledge, our study is the first to develop and validate a risk prediction model specific for AKI following ACS and PCI, based on a large nationwide cohort. The risk factor analysis revealed 16 variables as risk factors, including age, diabetes mellitus, ventilator use, prior AKI, number of intervened vessels, CKD, IABP use, cardiogenic shock, female sex, peripheral arterial disease, hypertension, and heart failure. We propose the ADVANCIS score, namely 5 patient-related characteristics, age, diabetes mellitus, prior AKI, CKD, and cardiogenic shock, and 3 procedure-related characteristics, number of intervened vessels, ventilator use, and IABP use. The discriminative power of the ADVANCIS model is equal to that of the full model for predicting AKI following ACS and PCI.

Among the 8 variables, age, diabetes mellitus, prior AKI, CKD, and shock are all known universal risk factors for AKI. The number of intervened vessels not only reflects the severity of coronary artery disease but also provides an estimate of the amount of administrated contrast media. IABP use not only is a marker of significant haemodynamic instability but also potentially confers additional hazards to the kidneys by causing atheroemboli during the procedure or occluding renal blood flow, if the pump is malpositioned [@B13].

The ADVANCIS score provides an incremental risk stratification, and enables clinicians to quickly and accurately predict the risk of AKI after PCI for ACS. A score of ≤5 was associated with a probability of \<5%, a score of ≥13 corresponded to a probability of \>50%, and a score of ≥18 predicted a probability of \>90%. High-risk patients require frequent monitoring; prophylactic strategies, including avoidance of nephrotoxic agents; early intervention to reduce the AKI severity; or prompt management including timely renal-replacement therapy.

AKI is a crucial risk factor for short-term and long-term mortality [@B22]. Our study showed that the ADVANCIS model had excellent discriminative power in predicting in-hospital mortality. An ADVANCIS score ≥ 6 is associated with significantly higher in-hospital mortality in patients with ACS after they receive PCI. ADVANCIS scores of ≤5 (low risk), 6-7 (moderate risk), and ≥8 (high risk) were associated with probabilities of in-hospital mortality of \<1%, \<20%, and \<40%, respectively.

To further evaluate the potential of the ADVANCIS model in facilitating clinical decision-making and improving patient outcomes, further prospective validation is necessary. The incorporation of novel biomarkers or other clinical parameters may provide additional prognostic value and warrants further investigation.

Despite the large sample size, a central limitation of this study was its retrospective nature. Information about the type of ACS, such as STEMI or NSTEMI, was not available. Laboratory data of blood or urine tests, fluid status, urine output, and left ventricular ejection fraction could not be assessed. Information regarding the type and volume of contrast medium, and the prophylactic strategy was lacking. Finally, our study did not evaluate long term mortality and renal outcome.

In conclusion, the ADVANCIS score is a potentially useful clinical tool to assess the risk of incident AKI and hospital mortality after PCI for ACS, thereby enabling prompt prevention and intervention.

Methods
=======

Data collection
---------------

Retrospective data were collected from the Taiwan National Health Insurance Research Database (NHIRD), which was established by the Taiwan National Health Insurance Administration and covers medical benefit claims for more than 99% of the more than 23 million residents of Taiwan [@B23]. The NHIRD provides comprehensive and accurate records of beneficiaries, including ambulatory visits, inpatient care, disease diagnosis codes, and medication prescriptions. All clinical diagnoses are recorded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The records and information of the patients were deidentified to ensure patient anonymity. The NHIRD has been widely used in epidemiology studies of cardiovascular disease and cerebral vascular disease [@B24]-[@B26]. The agreement of comorbidity coding of NHIRD with traditional electronic medical records has been validated [@B27]. The Institutional Review Board at Linkou Chang Gung Memorial Hospital approved this study and waived the requirement for informed consent.

Study populations
-----------------

As illustrated in Figure [1](#F1){ref-type="fig"}, this study identified 201,526 patients who were admitted with a diagnosis of ACS (ICD-9-CM 410) between January 1, 1997 and December 31, 2011. This coding was validated in a previous study and achieved a positive predicted value of 93% [@B24]. Among them, 85,008 patients receiving PCI were enrolled. We excluded patients with (1) an unknown sex (n = 46), (2) age \< 18 years (n = 6), and (3) end-stage renal disease requiring long-term dialysis (ICD-9-CM 585 and corresponding catastrophic illness certificate) (n = 2,770). Finally, 82 186 eligible patients were enrolled and randomly divided according to a 7:3 ratio to generate a training and validation cohort, respectively.

Outcomes and comorbidities
--------------------------

The index hospitalization was defined as the date on which patients were admitted for ACS. The primary outcome was incident AKI (ICD-9-CM 584.9) with or without de novo dialysis during index admission. The disease code of AKI was validated in a previous study and achieved a sensitivity of 92% and a positive predicted value of 100% [@B27]. De novo dialysis was defined as dialysis initiated during the index admission. The secondary outcome was mortality during the index admission and the definition was also reported [@B27]. Cardiogenic shock was identified as (1) the use of \>400 mg of dopamine or (2) the use of \>0 mg of epinephrine or norepinephrine during the index admission [@B28], [@B29].

Statistical analysis
--------------------

The distribution of baseline characteristics and clinical information was compared between the patients with and those without AKI by using the Student *t* test for continuous variables and the chi-square test for categorical variables in the training and validation cohorts. In the next step, we developed a multivariable logistic model (named full model) including baseline characteristics (i.e., sex, age, comorbidities, and major procedures during index admission) as explanatory variables. Subsequently, we selected clinically relevant variables to develop a parsimonious model (named reduced model or ADVANCIS) based on the training cohort data. The multi-collinearity among predictors in reduced model was tested using variance inflation factor (VIF). To assess the extent of loss in discriminating incident AKI attributable to the unselected variables (i.e., sex or prior stroke), we compared the areas under the receiver operation characteristic curve (AUROC) between the full and reduced models [@B30].

According to the results of the multivariable logistic model based on the training cohort data, we calculated a simplified point system [@B12] to demonstrate the associations between explanatory variables (covariates) and incident AKI. The points system rounds off the regression coefficients derived from the multivariable logistic model. Firstly, we identified a continuous predictor (i.e. age) with a wide range of values as the reference variable, categorized it into relevant categories. Furthermore, we obtained reference values for each category and categorized the other predictors. Finally, the reference value of each predictor category was calculated according to the value of its regression coefficient relative to that of the reference variable.

Furthermore, to evaluate the generalizability of the reduced model (ADVANCIS), we compared the AUROCs between the validation cohort (estimates were not restricted) and a validation cohort that was derived from the training cohort (estimates of validation cohort were restricted to being equal to those of the training cohort). A *P* value of \<0.05 was considered statistically significant. Data analysis as well as random sampling were conducted using IBM SPSS 22 (IBM SPSS, Armonk, NY, USA: IBM Corp).
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###### 

Baseline characteristics and clinical information in the training and validation cohorts

                                               Training        Validation      
  -------------------------------------------- --------------- --------------- -------
  Age (years)                                                                  0.064
  \< 75 years                                  43,994 (76.5)   18,707 (75.9)   
  ≥ 75 years                                   13,536 (23.5)   5,949 (24.1)    
  Male                                         44,785 (77.8)   19,077 (77.4)   0.135
  Comorbidities                                                                
  Diabetes mellitus                            20,089 (34.9)   8,567 (34.7)    0.633
  Hypertension                                 30,847 (53.6)   13,297 (53.9)   0.412
  Coronary artery disease                      8,385 (14.6)    3,648 (14.8)    0.412
  Prior myocardial infarction                  6,615 (11.5)    2,768 (11.2)    0.261
  Heart failure                                3,804 (6.6)     1,677 (6.8)     0.319
  Chronic kidney disease                       1,255 (2.2)     555 (2.3)       0.534
  Prior AKI                                    870 (1.5)       358 (1.5)       0.514
  Prior stroke                                 5,989 (10.4)    2,536 (10.3)    0.591
  Peripheral arterial disease                  2,023 (3.5)     950 (3.9)       0.018
  Gout                                         4,343 (7.5)     1,823 (7.4)     0.438
  Malignancy                                   2,421 (4.2)     1,005 (4.1)     0.385
  Number of intervened vessels                                                 0.995
  1                                            46,892 (81.5)   20,097 (81.5)   
  2                                            9,496 (16.5)    4,067 (16.5)    
  3                                            1,142 (2.0)     492 (2.0)       
  Cardiogenic shock                            13,593 (23.6)   5,738 (23.3)    0.271
  IABP use                                     6,684 (11.6)    2,733 (11.1)    0.028
  Ventilator use                               6,228 (10.8)    2,597 (10.5)    0.214
  Dosage of inotropic medications                                              
  Dopamine (×10^3^ mg)                         0.5±2.4         0.5±2.2         0.633
  Norepinephrine (mg)                          0.6±4.7         0.6±3.8         0.080
  Epinephrine (mg)                             2.6±23.0        2.8±39.1        0.496
  Other medications                                                            
  Aspirin                                      54,310 (94.4)   23,234 (94.2)   0.333
  Clopidogrel                                  51,372 (89.3)   22,192 (90.0)   0.002
  B-blocker                                    36,287 (63.1)   15,721 (63.8)   0.061
  ACEi/ARB                                     43,315 (75.3)   18,695 (75.8)   0.104
  Calcium channel blocker                      17,783 (30.9)   7,517 (30.5)    0.228
  Statin                                       27,133 (47.2)   11,808 (47.9)   0.056
  PPI                                          4,333 (7.5)     1,883 (7.6)     0.601
  GP IIb/IIIa                                  1,082 (1.9)     452 (1.8)       0.645
  Metformin                                    8,451 (14.7)    3,620 (14.7)    0.977
  ICU stays (days)                             4.2±6.7         4.2±7.3         0.457
  Hospital stays (days)                        9.3±16.5        9.3±14.9        0.684
  In hospital mortality                        3,746 (6.5)     1,572 (6.4)     0.469
  Major bleeding requiring blood transfusion   9,949 (17.3)    4,242 (17.2)    0.757

ACEi, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; GP, glycoprotein; IABP, intra-aortic balloon pump; ICU, intensive care unit; PPI, proton pump inhibitor.

###### 

Baseline characteristics and clinical information in the training and validation cohorts with and without AKI

                                               Training cohort (*N* = 57,530)   Validation cohort (*N* = 24,656)                                        
  -------------------------------------------- -------------------------------- ---------------------------------- --------- ------------ ------------- ---------
  Age (years)                                  71.1±11.7                        63.5±13.2                          \<0.001   70.8±12.1    63.7±13.4     \<0.001
  \< 75 years                                  1508(56.5)                       42486(77.4)                        \<0.001   665(57.4)    18042(76.8)   \<0.001
  ≥ 75 years                                   1162(43.5)                       12374(22.6)                        \<0.001   494(42.6)    5455(23.2)    \<0.001
  Male                                         1687(63.2)                       43098(78.6)                        \<0.001   713(61.5)    18364(78.2)   \<0.001
  Comorbidities                                                                                                                                         
  Diabetes mellitus                            1573(58.9)                       18516(33.8)                        \<0.001   676(58.3)    7891(33.6)    \<0.001
  Hypertension                                 1757(65.8)                       29090(53.0)                        \<0.001   779(67.2)    12518(53.3)   \<0.001
  Coronary artery disease                      682(25.5)                        7703(14.0)                         \<0.001   298(25.7)    3350(14.3)    \<0.001
  Prior myocardial infarction                  408(15.3)                        6207(11.3)                         \<0.001   185(16)      2583(11)      \<0.001
  Heart failure                                563(21.1)                        3241(5.9)                          \<0.001   245(21.1)    1432(6.1)     \<0.001
  Chronic kidney disease                       561(21.0)                        694(1.3)                           \<0.001   257(22.2)    298(1.3)      \<0.001
  Prior AKI                                    296(11.1)                        574(1.1)                           \<0.001   112(9.7)     246(1.1)      \<0.001
  Prior stroke                                 585(21.9)                        5404(9.9)                          \<0.001   237(20.5)    2299(9.8)     \<0.001
  Peripheral arterial disease                  297(11.1)                        1726(3.2)                          \<0.001   146(12.6)    804(3.4)      \<0.001
  Gout                                         256(9.6)                         4087(7.5)                          \<0.001   113(9.8)     1710(7.3)     0.002
  Malignancy                                   197(7.4)                         2224(4.1)                          \<0.001   85(7.3)      920(3.9)      \<0.001
  Number of intervened vessels                                                                                     \<0.001                              \<0.001
  1                                            1918(71.8)                       44974(82.0)                                  853(73.6)    19244(81.9)   
  2                                            650(24.3)                        8846(16.1)                                   261(22.5)    3806(16.2)    
  3                                            102(3.8)                         1040(1.9)                                    45(3.9)      447(1.9)      
  Cardiogenic shock                            1787(66.9)                       11806(21.5)                        \<0.001   750(64.7)    4988(21.2)    \<0.001
  IABP use                                     912(34.2)                        5772(10.5)                         \<0.001   379(32.7)    2354(10)      \<0.001
  Ventilator use                               1257(47.1)                       4971(9.1)                          \<0.001   554(47.8)    2043(8.7)     \<0.001
  Dosage of inotropic medications                                                                                                                       
  Dopamine (×10^3^ mg)                         3.0±6.2                          0.4±2.0                            \<0.001   2.9±5.8      0.4±1.8       \<0.001
  Norepinephrine (mg)                          5.1±14.4                         0.4±3.5                            \<0.001   4.1±11.1     0.4±2.9       \<0.001
  Epinephrine (mg)                             16.1±59.2                        2±19.3                             \<0.001   21.9±167     1.8±14.6      \<0.001
  Other medications                                                                                                                                     
  Aspirin                                      2341(87.7)                       51969(94.7)                        \<0.001   1010(87.1)   22224(94.6)   \<0.001
  Clopidogrel                                  2452(91.8)                       48920(89.2)                        \<0.001   1079(93.1)   21113(89.9)   \<0.001
  B-blocker                                    1547(57.9)                       34740(63.3)                        \<0.001   682(58.8)    15039(64)     \<0.001
  ACEi/ARB                                     1596(59.8)                       41719(76.1)                        \<0.001   672(58)      18023(76.7)   \<0.001
  Calcium channel blocker                      1343(50.3)                       16440(30.0)                        \<0.001   591(51)      6926(29.5)    \<0.001
  Statin                                       1069(40.0)                       26064(47.5)                        \<0.001   466(40.2)    11342(48.3)   \<0.001
  PPI                                          828(31.0)                        3505(6.4)                          \<0.001   338(29.2)    1545(6.6)     \<0.001
  GP IIb/IIIa                                  41(1.54)                         1041(1.9)                          0.179     18(1.6)      434(1.9)      0.466
  Metformin                                    224(8.4)                         8227(15)                           \<0.001   95(8.2)      3525(15)      \<0.001
  ICU stays (days)                             13.2±17.5                        3.8±5.3                            \<0.001   13±15.8      3.7±6.3       \<0.001
  Hospital stays (days)                        26.7±34.4                        8.5±14.6                           \<0.001   28±41.4      8.4±11.4      \<0.001
  In hospital mortality                        908 (34.0)                       2,838 (5.2)                        \<0.001   385 (33.2)   1,187 (5.1)   \<0.001
  Major bleeding requiring blood transfusion   1965(73.6)                       7984(14.6)                         \<0.001   863(74.5)    3379(14.4)    \<0.001

ACEi, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; GP, glycoprotein; IABP, intra-aortic balloon pump; ICU, intensive care unit; PPI, proton pump inhibitor.

###### 

Risk factor analysis for incident AKI after PCI for ACS in training cohort

                                 Full model           Reduced model (ADVANCIS)                                             
  ------------------------------ ------------ ------- -------------------------- --------- -- ------- ------- ------------ ---------
  Age, year                      0.016        1.02    1.01-1.02                  \<0.001      0.021   1.02    1.02-1.03    \<0.001
  Diabetes mellitus              0.599        1.82    1.66-2.00                  \<0.001      0.736   2.09    1.91-2.28    \<0.001
  Ventilator use                 0.975        2.65    2.38-2.95                  \<0.001      1.000   2.72    2.45-3.02    \<0.001
  Prior AKI                      1.317        3.73    3.09-4.50                  \<0.001      1.486   4.42    3.67-5.32    \<0.001
  Number of intervened vessels                                                                                             
  2 vs 1                         0.275        1.32    1.19-1.46                  \<0.001      0.298   1.35    1.21-1.50    \<0.001
  3 vs 1                         0.651        1.92    1.51-2.43                  \<0.001      0.680   1.98    1.56-2.50    \<0.001
  Chronic kidney disease         2.431        11.38   9.86-13.13                 \<0.001      2.530   12.55   10.9-14.46   \<0.001
  IABP use                       0.586        1.80    1.62-2.00                  \<0.001      0.545   1.72    1.55-1.92    \<0.001
  Cardiogenic shock              1.216        3.37    3.02-3.77                  \<0.001      1.219   3.38    3.03-3.78    \<0.001
  Female sex                     0.178        1.19    1.09-1.32                  \<0.001                                   
  Prior stroke                   0.114        1.12    1.00-1.26                  0.054                                     
  Peripheral arterial disease    0.392        1.48    1.27-1.73                  \<0.001                                   
  Hypertension                   0.189        1.21    1.09-1.33                  \<0.001                                   
  Coronary artery disease        0.011        0.99    0.88-1.11                  0.850                                     
  Heart failure                  0.451        1.57    1.38-1.79                  \<0.001                                   
  Malignancy                     0.043        1.04    0.87-1.25                  0.637                                     
  Gout                           0.024        1.02    0.87-1.20                  0.771                                     

AKI, acute kidney injury; ACS, acute coronary syndrome; β = regression coefficient; aOR, adjusted odds ratio; CI, confidence interval; IABP, intra-aortic balloon pump.

###### 

ADVANCIS score and the risk of post-ACS AKI

  Single predictor                   Total points and risk (%)        
  ------------------------------ --- --------------------------- ---- ------
  Age, years                                                     0    0.5
  20 to 39                       0                               1    0.7
  40 to 59                       1                               2    1.1
  60 to 79                       2                               3    1.6
  ≥ 80                           3                               4    2.5
  Diabetes mellitus              1                               5    3.7
  Ventilator use                 2                               6    5.6
  Prior AKI                      3                               7    8.3
  Number of intervened vessels                                   8    12.2
  1                              0                               9    17.6
  2                              1                               10   24.6
  3                              2                               11   33.4
  Chronic kidney disease         6                               12   43.4
  IABP use                       1                               13   54.0
  Cardiogenic shock              3                               14   64.2
                                                                 15   73.3
                                                                 16   80.8
                                                                 17   86.6
                                                                 18   90.8
                                                                 19   93.8
                                                                 20   95.9
                                                                 21   97.2
                                                                 22   98.2

AKI, acute kidney injury; ACS, acute coronary syndrome; IABP, intra-aortic balloon pump
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